Antibody druggability screening process and evaluation strategy
Since the approval of OKT3 as the first therapeutic monoclonal antibody in 1986,there has been rapid development in antibody technology and antibody drugs.Monoclonal antibodies,antibody fragments,bi(multi)specific antibodies,fusion proteins,nanobodies,and antibody-drug conjugates(ADCs)have been introduced and play a significant role in the treatment of oncology,hematology,immunology,respiratory,metabolic and other related diseases.The process of antibody drug discovery involves multiple rounds of biological function and druggability assessments to identify the best candidate sequences that are safe,effective,stable,and scalable.This lays the foundation for the efficiency and success of drug development and clinical studies.In the phase of antibody drug discovery,"druggability screening and evaluation"has received increasing attention.It involves drug discovery and design,screening and optimization of lead molecules as well as the validation of candidate molecules,with the aim of detecting potential physicochemical risk factors and evaluating controllability to ensure the quality stability of the subsequent drug development process.This paper classifies and defines the process of druggability screening and evaluation in the antibody discovery phase,covering monoclonal antibodies,bispecific antibodies,nanobodies,ADCs and other related technologies and drug forms.It also summarizes the quality attributes and high-throughput detection technology that should be emphasized in the druggability screening and evaluation.The systematic elaboration of the druggability development process and strategy provides a reference for the druggability screening and evaluation of emerging innovative drugs,significantly improving the efficiency and success rate of antibody drug development.
antibodydiscoverydruggabilityscreening and evaluationhigh-throughput detection technology
万方数据
维普
